Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CanSino Biologics, Inc. Class H ( (HK:6185) ) has provided an announcement.
CanSino Biologics has received approval from China’s National Medical Products Administration for its DTcP Infant vaccine, a diphtheria, tetanus and acellular pertussis (three components) combined vaccine for children under two, marketed as Tripecia. Unlike existing co-purified products, each pertussis antigen in DTcP Infant is purified separately and blended in defined ratios, which the company says improves batch consistency and product stability.
The DTcP Infant shot is the first diphtheria, tetanus and acellular pertussis components vaccine to be launched in China and the first in CanSino’s DTcP portfolio to secure new drug approval. Management believes the regulatory green light lays the groundwork for future DTcP-based products for older age groups, supports more efficient launches of pipeline vaccines, and strengthens the company’s commercial portfolio and brand recognition, with potential implications for its competitive position in the pediatric vaccine market.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative vaccines. The company targets infectious diseases with advanced vaccine technologies and aims to expand its commercial portfolio and brand presence in both domestic and international markets.
Average Trading Volume: 961,329
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.09B
Learn more about 6185 stock on TipRanks’ Stock Analysis page.